COVID-19 infection has cardiovascular implications, both for risk and potentially long-term outcomes.

Members of the EU-CardioRNA COST Action CA17129 have set-up a CardioRNA COVID19 Task Force aiming to organize future collaborative research on cardiovascular complications in SARS-CoV-2-infected patients.

The first task force publication is now out in the European Heart Journal, where we explain our ideas, hopes and plans for global scientific collaboration and cooperation, to understand this phenomenon, monitor the lasting effects on the cardiovascular system and optimize diagnostics and care for COVID19 patients.

Link to the article here:

If you have access to blood samples of COVID19 patients and are interested to join our study on RNA biomarkers of COVID19, please do let us know.

The EHJ article is also posted on Twitter (@cost1729) and LinkedIn, so please ‘Like’ or share if you can!